4 hours ago
1
David Bautista
- The U.S. FDA has granted approval to Johnson & Johnson's (NYSE:JNJ) Inlexzo (gemcitabine intravesical system), for certain types of bladder cancer.
- While gemcitabine was first approved in 1998 and is currently approved for several different types of cancer, Inlexzo is different
English (US) ·